Skip to main content
Loading

Genetic Medicines’ Path to Scalability for Patients and Investors

February 26, 2024
More than 30 genetic medicine treatments have been approved by the FDA so far, with hundreds more in the clinical pipeline, but companies working in these newer modalities have been challenged by scaling up manufacturing and establishing reliable reimbursement paths. This panel will examine the risks and opportunities when commercializing genetic medicines and how best to fulfill the expectations of investors to support bringing these pioneering benefits to patients.
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP